149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8200
https://www.protagenic.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Garo H. Armen Ph.D. | Co-Founder & Executive Chairman of the Board | N/D | N/D | 1953 |
Dr. Alexander Kenneth Arrow C.F.A., M.D. | CFO & Secretary | 150k | N/D | 1971 |
Dr. Andrew Slee Ph.D. | Chief Operating Officer | N/D | N/D | 1950 |
Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director | N/D | N/D | 1951 |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
L'ISS Governance QualityScore di Protagenic Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.